BLAINJECTIONINJECTABLE
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 22m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REVCOVI (elapegademase-lvlr) is an enzyme replacement therapy administered by injection for adenosine deaminase (ADA) deficiency, a rare inherited metabolic disorder affecting immune function. The drug works by replacing the deficient ADA enzyme, allowing patients to metabolize toxic metabolites and restore immune competence. It represents a targeted treatment for a ultra-rare genetic condition with limited patient populations.
$0.028BPart D
PeakProduct is at peak lifecycle stage with modest Part D spending (~$28M in 2023), indicating a niche market with limited commercial team expansion opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Registry Study of Revcovi Treatment in Patients With ADA-SCID
Started Sep 2019
32 enrolled
Adenosine Deaminase Severe Combined Immunodeficiency
Career Relevance
Working on REVCOVI offers deep specialization in ultra-rare disease management and orphan drug commercialization, appealing to professionals seeking focused expertise in genetic disorders and niche patient populations. The lack of linked job postings reflects the product's mature, stable commercial phase with limited team growth, making this a role for specialists seeking specialization rather than career expansion.
Medical Science Liaison (Metabolic Disorders specialty)
Worked on REVCOVI at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.